Humana reportedly in talks to buy Kindred

John Gregory | | Health Exec | Economics

Continuing a flurry of big mergers and acquisitions around healthcare as 2017 winds down, health insurer Humana is reportedly in “advanced talks” to buy Kindred Healthcare with help from two private equity firms.

First reported by the Wall Street Journal, the rumored deal would involve the two firms—TPG and Welsh, Carson, Anderson & Stowe—acquiring Kindred’s 77 long-term acute care hospitals and 19 rehabilitation centers. Humana and the firms together would take over Kindred’s home health and hospice care business. The deal would value Kindred’s stock at $9 per share.

Kindred is the largest home health and hospice operator in the U.S., but has struggled with its $3.2 billion debt load, much of it from its 2015 acquisition of Gentiva Health Services. It’s been rumored to be a takeover target this year and has scaled back in some areas, announcing in Nov. 2016 it would be divesting its 91 nursing homes.

Read more at the link below:

Humana and Private-Equity Firms in Talks to Buy Kindred Healthcare

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.